T Seto

Summary

Country: Japan

Publications

  1. pmc A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer
    T Seto
    Division of Respiratory Diseases, Kumamoto Regional Medical Center, 5 Cho me 16 10 Honjou, Kumamoto City 860 0811, Japan
    Br J Cancer 86:1701-4. 2002
  2. ncbi request reprint Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging
    F Imamura
    Department of Pulmonary Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka, Japan
    Lung Cancer 27:189-97. 2000
  3. pmc UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Y Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    Br J Cancer 93:770-3. 2005
  4. ncbi request reprint [A case of recurrent breast cancer successfully treated with docetaxel]
    T Nakagawa
    Dept. of Breast and Endocrinologic Surgery, Nakadori General Hospital
    Gan To Kagaku Ryoho 28:383-5. 2001
  5. pmc Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial
    T Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame, Fukuoka 811 1395, Japan
    Br J Cancer 95:717-21. 2006

Detail Information

Publications5

  1. pmc A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer
    T Seto
    Division of Respiratory Diseases, Kumamoto Regional Medical Center, 5 Cho me 16 10 Honjou, Kumamoto City 860 0811, Japan
    Br J Cancer 86:1701-4. 2002
    ..The combination chemotherapy UFT and gemcitabine was well tolerated and may benefit patients with advanced non-small cell lung cancer. A multicentre phase II study using a 3-weekly regimen is in progress...
  2. ncbi request reprint Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging
    F Imamura
    Department of Pulmonary Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka, Japan
    Lung Cancer 27:189-97. 2000
    ..These results mean that almost all lesions in skeletal scintigraphy derived from bone marrow metastases. Furthermore, appreciable volume of cancer cells is present in bone marrow before osteolytic changes appear in skeletal scintigraphy...
  3. pmc UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
    Y Ichinose
    Department of Thoracic Oncology, National Kyushu Cancer Center, Minami Ku, Fukuoka, Japan
    Br J Cancer 93:770-3. 2005
    ..This combination chemotherapy demonstrated a promising effectiveness and acceptable toxicity in patients with advanced NSCLC, even in patients older than 75 years. ...
  4. ncbi request reprint [A case of recurrent breast cancer successfully treated with docetaxel]
    T Nakagawa
    Dept. of Breast and Endocrinologic Surgery, Nakadori General Hospital
    Gan To Kagaku Ryoho 28:383-5. 2001
    ..Adverse reactions were grade 4 neutropenia, grade 2 alopecia, fever, and grade 1 edema. She received medroxyprogesterone acetate after the chemotherapy and has been well without re-growth of any metastases for over eight months...
  5. pmc Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial
    T Seto
    Department of Thoracic Oncology, National Kyushu Cancer Center, Notame, Fukuoka 811 1395, Japan
    Br J Cancer 95:717-21. 2006
    ..The median survival time of all patients was 239 days. Hypotonic cisplatin treatment for malignant pleural effusion of NSCLC is therefore considered to be feasible and effective. A phase III study of HPT is thus warranted...